AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$35.71 USD
+2.01 (5.96%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $35.72 +0.01 (0.03%) 6:48 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ANAB 35.71 +2.01(5.96%)
Will ANAB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANAB
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
ANAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
Other News for ANAB
First Week of September 20th Options Trading For AnaptysBio (ANAB)
AnaptysBio’s Promising Pipeline and Rosnilimab’s Best-in-Class Potential Justify Buy Rating
AnaptysBio initiated with bullish view at H.C. Wainwright, here's why
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Arm and Accenture upgraded: Wall Street's top analyst calls